BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trapp S, Brierley DI. Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br J Pharmacol 2021. [PMID: 34323288 DOI: 10.1111/bph.15638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Su Y, Zhang S, Wu Z, Liu W, Chen J, Deng F, Chen F, Zhu D, Hou K. Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1054946] [Reference Citation Analysis]
2 Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease. Mol Psychiatry 2023;28:217-29. [PMID: 36258018 DOI: 10.1038/s41380-022-01792-4] [Reference Citation Analysis]
3 Wagner S, Brierley DI, Leeson-Payne A, Jiang W, Chianese R, Lam BYH, Dowsett GKC, Cristiano C, Lyons D, Reimann F, Gribble FM, Martinez de Morentin PB, Yeo GSH, Trapp S, Heisler LK. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression. Mol Metab 2022;68:101665. [PMID: 36592795 DOI: 10.1016/j.molmet.2022.101665] [Reference Citation Analysis]
4 Schulz C, Vezzani C, Kroemer NB. How gut hormones shape reward: a systematic review of the role of ghrelin and GLP-1 in human fMRI.. [DOI: 10.1101/2022.11.30.518539] [Reference Citation Analysis]
5 Zheng H, López-Ferreras L, Krieger JP, Fasul S, Cea Salazar V, Valderrama Pena N, Skibicka KP, Rinaman L. A Cre-driver rat model for anatomical and functional analysis of glucagon (Gcg)-expressing cells in the brain and periphery. Mol Metab 2022;66:101631. [PMID: 36368622 DOI: 10.1016/j.molmet.2022.101631] [Reference Citation Analysis]
6 Zheng H, López-ferreras L, Krieger J, Fasul S, Salazar VC, Pena NV, Skibicka KP, Rinaman L. A Cre-Driver Rat Model for Anatomical and Functional Analysis of Glucagon(Gcg)-Expressing Cells in the Brain and Periphery.. [DOI: 10.1101/2022.10.10.511573] [Reference Citation Analysis]
7 Harada K, Takashima M, Kitaguchi T, Tsuboi T. Exocytotic dynamics of glucagon-like peptide-1 from enteroendocrine L cell line is regulated by actin polymerization.. [DOI: 10.1101/2022.09.14.508035] [Reference Citation Analysis]
8 Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X, Li T. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther 2022;7:298. [PMID: 36031641 DOI: 10.1038/s41392-022-01149-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 de Wouters d’Oplinter A, Huwart SJP, Cani PD, Everard A. Gut microbes and food reward: From the gut to the brain. Front Neurosci 2022;16:947240. [DOI: 10.3389/fnins.2022.947240] [Reference Citation Analysis]
10 Zhang J, Li T, Wu Q, Qin Z, Wei B, Wu R, Guo X, Xiao H, Wu W. Emetic Response to T-2 Toxin Correspond to Secretion of Glucagon-like Peptide-17–36 Amide and Glucose-Dependent Insulinotropic Polypeptide. Toxins 2022;14:389. [DOI: 10.3390/toxins14060389] [Reference Citation Analysis]
11 D'agostino G, Luckman SM. Brainstem peptides and peptidergic neurons in the regulation of appetite. Current Opinion in Endocrine and Metabolic Research 2022;24:100339. [DOI: 10.1016/j.coemr.2022.100339] [Reference Citation Analysis]
12 Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022;2:100018. [DOI: 10.1016/j.obpill.2022.100018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Manavi MA. Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides 2022;94:102250. [PMID: 35561568 DOI: 10.1016/j.npep.2022.102250] [Reference Citation Analysis]
14 Ahmed H, Leyrolle Q, Koistinen V, Kärkkäinen O, Layé S, Delzenne N, Hanhineva K. Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes 2022;14:2102878. [PMID: 35903003 DOI: 10.1080/19490976.2022.2102878] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Scheen AJ. Médicaments anti-obésité : leçons des échecs pour l’avenir. Médecine des Maladies Métaboliques 2021;15:734-743. [DOI: 10.1016/j.mmm.2021.10.012] [Reference Citation Analysis]